New Delhi: The approval for Bharat Biotech’s Covaxin for use in the 2-18 years age group may take time before it is made available for people.
The Drugs Controller General of India (DCGI) is carefully examining the recommendation by the expert panel and evaluating several factors, Business Standard reported on Wednesday.
Last week, the panel had recommended the usage of Covaxin for children as young as two. The final approval for 2-18 years old is under expert opinion and evaluation.
The DCGI will hold discussions with the health minister, PMO, and Bharat Biotech before granting EUA to Covaxin, the report quoted sources as saying.